DOMA Perpetual Capital to nominate four candidates to Pacira’s board

DOMA Perpetual Capital Management, which beneficially owns approximately 4.14% of the outstanding shares of common stock of Pacira (PCRX) BioSciences, announced that it intends to nominate four highly-qualified, independent director candidates at the company’s 2025 annual meeting of stockholders, and stated that it has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the company. DOMA further stated that it believes strongly in the value of the company’s intellectual property and that the company’s stock is grossly undervalued and urged the company to immediately commence a stock tender offer for 10M shares using its substantial cash on hand, and then execute its already-approved $150M buyback program using the company’s healthy and growing free cash flow.